Top

Head & Face Medicine

Published in:

Open Access 01-12-2021 | Research

Investigating resistin like beta (RETNLB) as a tumor promoter for oral squamous cell carcinoma

Authors: Hong Jin, Hui Miao, Yuan-Wen Nie, Yang-Yang Lin

Published in: Head & Face Medicine | Issue 1/2021

Abstract

Background

Oral cavity cancer ranks the sixth most common malignancy worldwide, of which oral squamous cell carcinoma is the predominant type. This study aimed to investigate the function and the underlying mechanism of resistin like beta (RETNLB) in oral squamous cell carcinoma.

Methods

The data of oral squamous cell carcinoma samples from The Cancer Genome Atlas database was used to examine RETNLB expression and assess its correlation with the clinical outcomes. Biological functions of RETNLB on the growth, invasion and migration of cells were determined by cell counting kit 8, clonogenic growth, and Transwell assays. Gene set enrichment analysis was utilized to identify the important gene sets associated with RETNLB expression, which was further confirmed by western blot.

Results

We found that RETNLB was upregulated in oral squamous cell carcinoma tissues and cells. High expression of RETNLB was closely linked to age and pathological tumor, and significantly related to poor survival of oral squamous cell carcinoma patients. Further functional experiments showed that knockdown of RETNLB significantly reduced the viability, mobility and invasiveness of cells. Moreover, gene set enrichment analysis suggested that Toll-like receptor signaling pathway was significantly correlated with high RETNLB expression. Further western blot analysis verified that silencing RETNLB could notably suppress the protein levels of Toll-like receptor 2, Toll-like receptor 4 and phosphor- extracellular signal-regulated kinase.

Conclusions

These results suggested that downregulation of RETNLB may restrain the progression of oral squamous cell carcinoma by inactivating TLR/2/4/ERK pathway.

Polanska H, Raudenska M, Gumulec J, Sztalmachova M, Adam V, Kizek R, et al. Clinical significance of head and neck squamous cell cancer biomarkers. Oral Oncol. 2014;50(3):168–77. https://doi.org/10.1016/j.oraloncology.2013.12.008.CrossRefPubMed

Mortazavi H, Baharvand M, Mehdipour M. Oral potentially malignant disorders: an overview of more than 20 entities. J Dent Res Dent Clin Dent Prospects. 2014;8(1):6–14. https://doi.org/10.5681/joddd.2014.002.CrossRefPubMedPubMedCentral

Lingen MW, Kalmar JR, Karrison T, Speight PM. Critical evaluation of diagnostic aids for the detection of oral cancer. Oral Oncol. 2008;44(1):10–22. https://doi.org/10.1016/j.oraloncology.2007.06.011.CrossRefPubMed

Valdez JA, Brennan MT. Impact of Oral Cancer on quality of life. Dent Clin N Am. 2018;62(1):143–54. https://doi.org/10.1016/j.cden.2017.09.001.CrossRefPubMed

Liu S, Liu L, Ye W, Ye D, Wang T, Guo W, et al. High vimentin expression associated with lymph node metastasis and predicated a poor prognosis in Oral squamous cell carcinoma. Sci Rep. 2016;6(1):38834. https://doi.org/10.1038/srep38834.CrossRefPubMedPubMedCentral

Shibahara T. Oral cancer -diagnosis and therapy. Clin Calcium. 2017;27(10):1427–33 DOI: CliCa171014271433.PubMed

Pine GM, Batugedara HM, Nair MG. Here, there and everywhere: Resistin-like molecules in infection, inflammation, and metabolic disorders. Cytokine. 2018;110:442–51. https://doi.org/10.1016/j.cyto.2018.05.014.CrossRefPubMedPubMedCentral

Horsnell WGC, Dewals BG. RELMs in the realm of helminths. Trends Parasitol. 2016;32(7):512–4. https://doi.org/10.1016/j.pt.2016.04.011.CrossRefPubMed

Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci U S A. 2001;98(2):502–6. https://doi.org/10.1073/pnas.98.2.502.CrossRefPubMedPubMedCentral

10.

Schwartz DR, Lazar MA. Human resistin: found in translation from mouse to man. Trends Endocrinol Metab. 2011;22(7):259–65. https://doi.org/10.1016/j.tem.2011.03.005.CrossRefPubMedPubMedCentral

11.

Shojima N, Sakoda H, Ogihara T, Fujishiro M, Katagiri H, Anai M, et al. Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes. 2002;51(6):1737–44. https://doi.org/10.2337/diabetes.51.6.1737.CrossRefPubMed

12.

Hu WW, Tang CH, Sun Y, et al. Correlation between resistin gene polymorphism and clinical aspects of lung cancer. Medicine (Baltimore). 2017;96:e9485.CrossRef

13.

Singh S, Chouhan S, Mohammad N, Bhat MK. Resistin causes G1 arrest in colon cancer cells through upregulation of SOCS3. FEBS Lett. 2017;591(10):1371–82. https://doi.org/10.1002/1873-3468.12655.CrossRefPubMed

14.

Zheng LD, Tong QS, Weng MX, He J, Lv Q, Pu JR, et al. Enhanced expression of resistin-like molecule beta in human colon cancer and its clinical significance. Dig Dis Sci. 2009;54(2):274–81. https://doi.org/10.1007/s10620-008-0355-2.CrossRefPubMed

15.

Zheng L, Weng M, He J, Yang X, Jiang G, Tong Q. Expression of resistin-like molecule beta in gastric cancer: its relationship with clinicopathological parameters and prognosis. Virchows Arch. 2010;456(1):53–63. https://doi.org/10.1007/s00428-009-0861-4.CrossRefPubMed

16.

Jiang R, Zhao C, Wang X, Wang S, Sun X, Tian Y, et al. Resistin-like molecule-beta promotes invasion and migration of gastric carcinoma cells. Med Sci Monit. 2016;22:937–42. https://doi.org/10.12659/MSM.895598.CrossRefPubMedPubMedCentral

17.

Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol. 2010;11(5):373–84. https://doi.org/10.1038/ni.1863.CrossRefPubMed

18.

Palani CD, Ramanathapuram L, Lam-Ubol A, Kurago ZB. Toll-like receptor 2 induces adenosine receptor A2a and promotes human squamous carcinoma cell growth via extracellular signal regulated kinases (1/2). Oncotarget. 2018;9(6):6814–29. https://doi.org/10.18632/oncotarget.23784.CrossRefPubMed

19.

Artis D, Wang ML, Keilbaugh SA, He W, Brenes M, Swain GP, et al. RELMbeta/FIZZ2 is a goblet cell-specific immune-effector molecule in the gastrointestinal tract. Proc Natl Acad Sci U S A. 2004;101(37):13596–600. https://doi.org/10.1073/pnas.0404034101.CrossRefPubMedPubMedCentral

20.

Rajala MW, Obici S, Scherer PE, Rossetti L. Adipose-derived resistin and gut-derived resistin-like molecule-beta selectively impair insulin action on glucose production. J Clin Invest. 2003;111(2):225–30. https://doi.org/10.1172/JCI16521.CrossRefPubMedPubMedCentral

21.

Hildebrandt MA, Hoffmann C, Sherrill-Mix SA, et al. High-fat diet determines the composition of the murine gut microbiome independently of obesity. Gastroenterology. 2009;137:1716–24.e1–2.CrossRef

22.

Graveleau C, Zaha VG, Mohajer A, Banerjee RR, Dudley-Rucker N, Steppan CM, et al. Mouse and human resistins impair glucose transport in primary mouse cardiomyocytes, and oligomerization is required for this biological action. J Biol Chem. 2005;280(36):31679–85. https://doi.org/10.1074/jbc.M504008200.CrossRefPubMed

23.

Lin K, Huang J, Luo H, et al. Development of a prognostic index and screening of potential biomarkers based on immunogenomic landscape analysis of colorectal cancer. Aging (Albany NY). 2020;12:5832–57.CrossRef

24.

Zheng LD, Yang CL, Qi T, Qi M, Tong L, Tong QS. Effects of resistin-like molecule beta over-expression on gastric cancer cells in vitro. World J Gastroenterol. 2012;18(8):754–66. https://doi.org/10.3748/wjg.v18.i8.754.CrossRefPubMedPubMedCentral

25.

Meng X, Zhang K, Kong J, Xu L, An G, Qin W, et al. Deletion of resistin-like molecule-beta attenuates angiotensin II-induced abdominal aortic aneurysm. Oncotarget. 2017;8(61):104171–81. https://doi.org/10.18632/oncotarget.22042.CrossRefPubMedPubMedCentral

26.

Ng LK, Hussaini HM, Rich AM, Seymour GJ. TLR2 expression in oral cancer, dysplastic and hyperplastic lesions. Pathology. 2009;41:64–5. https://doi.org/10.1097/01268031-200941001-00146.CrossRef

27.

Ren WH, Zhang LM, Liu HQ, Gao L, Chen C, Qiang C, et al. Protein overexpression of CIRP and TLR4 in oral squamous cell carcinoma: an immunohistochemical and clinical correlation analysis. Med Oncol. 2014;31(8):120. https://doi.org/10.1007/s12032-014-0120-7.CrossRefPubMed

28.

Sun Z, Luo Q, Ye D, Chen W, Chen F. Role of toll-like receptor 4 on the immune escape of human oral squamous cell carcinoma and resistance of cisplatin-induced apoptosis. Mol Cancer. 2012;11(1):33. https://doi.org/10.1186/1476-4598-11-33.CrossRefPubMedPubMedCentral

29.

Fang C, Meng Q, Wu H, Eid G, Zhang G, Zhang X, et al. Resistin-like molecule-beta is a human airway remodelling mediator. Eur Respir J. 2012;39(2):458–66. https://doi.org/10.1183/09031936.00107811.CrossRefPubMed

Title: Investigating resistin like beta (RETNLB) as a tumor promoter for oral squamous cell carcinoma
Authors: Hong Jin
Hui Miao
Yuan-Wen Nie
Yang-Yang Lin
Publication date: 01-12-2021
Publisher: BioMed Central
Published in: Head & Face Medicine / Issue 1/2021
Electronic ISSN: 1746-160X
DOI: https://doi.org/10.1186/s13005-021-00272-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Investigating resistin like beta (RETNLB) as a tumor promoter for oral squamous cell carcinoma

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

The use of solvent-preserved human and bovine cancellous bone blocks for lateral defect augmentation - an experimental controlled study in vivo

One year of COVID-19 pandemic: a cross sectional study on teaching oral and maxillofacial surgery

Targeted sequencing of NOTCH signaling pathway genes and association analysis of variants correlated with mandibular prognathism

Hyperspectral imaging and artificial intelligence to detect oral malignancy – part 1 - automated tissue classification of oral muscle, fat and mucosa using a light-weight 6-layer deep neural network

ANLN promotes carcinogenesis in oral cancer by regulating the PI3K/mTOR signaling pathway

Clinicopathological features of incidental parotid lesions